NEOLEUKIN THERAPEUTICS INC - COM (NLTX)

CUSIP: 64049K104

Q1 2023 13F Holders as of 31 Mar 2023

Type / Class
Equity / COM
Total 13F shares
15,050,814
Share change
-1,972,268
Total reported value
$10,534,008
Price per share
$0.70
Number of holders
35
Value change
-$1,345,378
Number of buys
8
Number of sells
26

Quarterly Holders Quick Answers

What is CUSIP 64049K104?
CUSIP 64049K104 identifies NLTX - NEOLEUKIN THERAPEUTICS INC - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of NEOLEUKIN THERAPEUTICS INC - COM (NLTX) as of Q1 2023

As of 31 Mar 2023, NEOLEUKIN THERAPEUTICS INC - COM (NLTX) was held by 35 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 15,050,814 shares. The largest 10 holders included BAKER BROS. ADVISORS LP, Lynx1 Capital Management LP, Redmile Group, LLC, BANK OF AMERICA CORP /DE/, VANGUARD GROUP INC, RENAISSANCE TECHNOLOGIES LLC, MORGAN STANLEY, MILLENNIUM MANAGEMENT LLC, BlackRock Inc., and GEODE CAPITAL MANAGEMENT, LLC. This page lists 35 institutional shareholders reporting positions in this security for the Q1 2023 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.